Blood-Brain Barrier Technologies and Global Markets
May 11, 2011
Wellesley, Mass. – According to a new technical market research report, BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS (PHM075A) from BCC Research (www.bccresearch.com), the value of the market for blood-brain barrier technologies was an estimated $12.3 million in 2010, but is expected to increase to $387 million in 2015, for a five-year compound annual growth rate (CAGR) of 99.3%.
The largest segment of the market, receptor media transport, is projected to increase at a CAGR of 98.9% to nearly $377 million in 2015, after being valued at an estimated $12.1 million in 2010.
The other market segment, carrier mediated transport, is estimated at $200,000 in 2010, and is expected to increase at a CAGR of 120.8% to reach $105 million in 2015.
Blood-brain barrier (BBB) technologies are going to open up a vast untapped potential in the growing central nervous system therapeutic market, where today growth is limited by the complexity of this layer in the brain that prevents the passage of many potentially useful molecules/compounds.
This report offers a picture of this technology potential that is on the verge of rapid increase. Therapeutics make up the main area of investment related to this technology; and, therefore, that is this report’s focus.
The scope of this study encompasses companies that develop technologies to enable the crossing of the BBB and drug development in which a quality of the development is enabling the crossing of the BBB in cases in which passage was previously impossible often due to size. BCC analyzes each technology, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.
BBB technology is a sub-industry of the pharmaceutical industry. In this space, companies’ receipts of grants and revenues from research collaborations and licensing deals in which sales of drugs are split represent millions of dollars and, eventually, billions over the next 10 years.
This study will be of interest to the biotechnology and pharmaceutical industries and related life science, analytics, drug discovery, and diagnostic test manufacturing companies as well as all those interested or actively working in drug and imaging agent research and investors in all of the above.
Blood-Brain Barrier Technologies and Global Markets( PHM075A )
Publish Date: Mar 2011
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Pharmaceuticals
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum
- Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030
- AI in Clinical Trials Poised for Rapid Growth with a 22.6% CAGR Forecast
Reports from Pharmaceuticals
Recent News
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand